Denali Therapeutics Inc.

As of June 30, 2026, Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh carries a market capitalization of 13.92B, placing it among publicly traded companies globally. Its enterprise value stands at 10.41B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh's next confirmed earnings release is scheduled for November 11, 2026.

As of June 30, 2026, Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh has 690.44M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 843.84, and the price-to-book ratio stands at 3.22.

These figures are as of June 30, 2026. The EV/Sales ratio of 558.84 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.41B versus a market cap of 13.92B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh maintains a current ratio of 8.37, meaning it holds 8.4x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2026, Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh posted a negative return on equity (ROE) of -54.93, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -44.01, reflecting losses generated across the asset base. The company generates approximately 38,589.49 in revenue per employee across its workforce of 482.75, a quick read on workforce productivity versus industry peers.

As of the close on July 13, 2026, Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh's stock has gained approximately 61.46% over the past 52 weeks.

Over the twelve months ended June 30, 2026, Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh generated 18.63M in revenue and converted that into -2.64B in net income, yielding earnings per share of -3.39. EBITDA reached -2.72B, while operating income came in at -2.81B.

As of June 30, 2026, Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh holds 3.67B in cash and equivalents against 166.48M in total debt, resulting in a net debt position of -1.04B. Total book value stands at 4.32B, with working capital of 3.43B providing operational flexibility.

Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh produced -2.24B in operating cash flow over the twelve months ended June 30, 2026. After subtracting -17.66M in capital expenditures, free cash flow totaled -2.26B - equivalent to -2.90 per share.

These figures cover the twelve months ended June 30, 2026. The operating margin of -15,058.19 and net profit margin of -14,191.20 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -14.38: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -15.80, meaning Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh raised more capital through share issuance and new debt than it returned via dividends and buybacks.

As of June 30, 2026, Denali Therapeutics Inc Shs Unsponsored Brazilian Depositary Receipt Repr 0.2 Sh has an Altman Z-Score of 1.24, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.